N-acetilcysteine prevents the <i>A</i>. <i>simplex</i> CE-induced TEER decrease. by Noelia Carballeda-Sangiao (2889611)

JNJ26993135 + BML-111 decreases permeability and enhances ZO-1 and claudin-1 induced by PAF but does not change TEER. by Kameljit K. Kalsi (16496511)

Basic characteristics of included studies. by Delai Zheng (18468980)

Subjects:

The mean and standard deviation of parameters. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

BA attenuated the decrease in the expression of ZO-1 and Occludin induced by LPS in Caco2 cells. by Luqiong Liu (11537092)

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Characteristics of included studies. by Su Hyun Seo (12568512)

Subjects:

GXM decreases the trans-endothelial electrical resistance (TEER) and transmigration of <i>C</i>. <i>neoformans</i> through HBECs in a blood brain barrier (BBB) model. by Hiu Ham Lee (15374677)

Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers. by Luqiong Liu (11537092)

“…The values are expressed as the means ± SDs and were analyzed according to the variance of the factorial design. **, *** and ****denote <i>p</i> < 0.01, < 0.001 and < 0.0001, respectively; ns  =  not significant.…”

Y-27632 synergized with BA to alleviate the decrease in the expression of and abnormal localization of ZO-1 and Occludin in LPS-induced Caco2 cells. by Luqiong Liu (11537092)

Posterior, mid-posterior, central, and mid-anterior corpus callosal volume significantly decreased with increasing risk of environmental lead exposure. by Andrew T. Marshall (10159199)

Specifications and outcomes of clinical trial studies included in the meta-analysis. by Junyin Pan (20700411)

Subjects:

Mean CCECAI over time between the placebo and FMT group. by Allison J. Collier (13977858)

Subjects:

Characteristics of the included studies. by Si He (3236646)

Subjects:

Key safety measures including adverse events. by Anuja Dokras (8679261)

“…Waist circumference (mean change (MC) −2.23 cm; 95% CI [−3.98, −0.49]; <i>p</i> = 0.01), BMI (MC −0.49 kg/m²; 95% CI [−0.88, −0.10[; <i>p</i> = 0.01), and android fat mass measured by DXA (MC −167 g; 95% CI [−264, −71[; <i>p</i> < 0.001) decreased in the COCP group over the study period whilst there was no statistically significant changes in these parameters in the metformin only group when compared to baseline.. …”

Significant outcome measures. by Patricia García-Pérez (19443332)

Subjects:

The characteristics of the 29 included studies. by Yu Xiong (1478806)

Subjects:

Certainty assessment for included outcomes. by Betelhem Abebe Andargie (19105769)

“…Heterogeneity was assessed using I² statistics, and potential publication bias was examined. The primary outcome was the mode of delivery, while secondary outcomes included duration of labor, Apgar score, and birth weight.…”

Results of the effect of dietary anthocyanins on health outcomes, including effect size and heterogeneity analysis. by Junyin Pan (20700411)

Subjects:

Flow diagram of the studies included in the meta-analysis. by Si He (3236646)

Subjects: